AI Science Tracker
EN

Identifying and understanding determinants of high healthcare costs for breast cancer: a quantile regression machine learning approach.

Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai · 23 Nov 2020 · medicine

Discovery

Identifying and understanding determinants of high healthcare costs for breast cancer: a quantile regression machine learning approach.

Source check: Source checked. Not independent scientific confirmation.

Finding: In 2,938 episodes from 2012–2018, chemotherapy drug and interval were prominent high-cost correlates; quantile analysis attributed 77% of reduced out-of-bag quantile loss to chemotherapy variables. Retrospective associations do not establish that changing a treatment or cost driver will causally reduce healthcare expenditures.

Technology: Quantile regression forests ranked variables associated with high-tail breast-cancer care expenditures in Oncology Care Model episodes.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Quantile regression forests ranked variables associated with high-tail breast-cancer care expenditures in Oncology Care Model episodes.
Test and result
In 2,938 episodes from 2012–2018, chemotherapy drug and interval were prominent high-cost correlates; quantile analysis attributed 77% of reduced out-of-bag quantile loss to chemotherapy variables.
Limitation / still unknown
Retrospective associations do not establish that changing a treatment or cost driver will causally reduce healthcare expenditures.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://link.springer.com/article/10.1186/s12913-020-05936-6

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.